Abstract:Traditional tumor models do not tend to accurately simulate tumor growth in vitro or enable personalized treatment and are particularly unable to discover more beneficial targeted drugs. To address this, this study describes the use of three-dimensional (3D) bioprinting technology to construct a 3D model with human hepatocarcinoma SMMC-7721 cells (3DP-7721) by combining gelatin methacrylate (GelMA) and poly(ethylene oxide) (PEO) as two immiscible aqueous phases to form a bioink and innovatively applying fluorescent carbon quantum dots for long-term tracking of cells. The GelMA (10%, mass fraction) and PEO (1.6%, mass fraction) hydrogel with 3:1 volume ratio offered distinct pore-forming characteristics, satisfactory mechanical properties, and biocompatibility for the creation of the 3DP-7721 model. Immunofluorescence analysis and quantitative real-time fluorescence polymerase chain reaction (PCR) were used to evaluate the biological properties of the model. Compared with the two-dimensional culture cell model (2D-7721) and the 3D mixed culture cell model (3DM-7721), 3DP-7721 significantly improved the proliferation of cells and expression of tumor-related proteins and genes. Moreover, we evaluated the differences between the three culture models and the effectiveness of antitumor drugs in the three models and discovered that the efficacy of antitumor drugs varied because of significant differences in resistance proteins and genes between the three models. In addition, the comparison of tumor formation in the three models found that the cells cultured by the 3DP-7721 model had strong tumorigenicity in nude mice. Immunohistochemical evaluation of the levels of biochemical indicators related to the formation of solid tumors showed that the 3DP-7721 model group exhibited pathological characteristics of malignant tumors, the generated solid tumors were similar to actual tumors, and the deterioration was higher. This research therefore acts as a foundation for the application of 3DP-7721 models in drug development research.

Bioprinting: A Tumor‐on‐a‐Chip System with Bioprinted Blood and Lymphatic Vessel Pair (Adv. Funct. Mater. 31/2019)

A Tumor‐on‐a‐Chip System with Bioprinted Blood and Lymphatic Vessel Pair

Perfusable Vessel-on-a-Chip for Antiangiogenic Drug Screening with Coaxial Bioprinting

Bioprinting of Novel 3D Tumor Array Chip for Drug Screening

3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (Adv. Healthcare Mater. 18/2023)

Bioprinting and its Use in Tumor-On-A-Chip Technology for Cancer Drug Screening: A Review

Tumor-on-a-chip: from bioinspired design to biomedical application

Bioprinted Multi‐Composition Array Mimicking Tumor Microenvironments to Evaluate Drug Efficacy with Multivariable Analysis

Three-dimensional bioprinting of in vitro tumor organoid and organ-on-a-chip models

Converging bioprinting and organoids to better recapitulate the tumor microenvironment

Embedded Bioprinting of Breast Tumor Cells and Organoids Using Low Concentration Collagen Based Bioinks

Bioprinting a 3D Vascular Construct for Engineering a Vessel-on-a-chip

Advanced tumor organoid bioprinting strategy for oncology research

The acoustic droplet printing of functional tumor microenvironments

Long-term cultured microvascular networks on chip for tumor vascularization research and drug testing

Advances in 3D Vascularized Tumor-on-a-Chip Technology

Current advances of 3D-bioprinted microfluidic models with hydrogel bioinks and their applications in drug screening

3D Bioprinting of in Vitro Porous Hepatoma Models: Establishment, Evaluation, and Anticancer Drug Testing

An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells.

The Prospects for Bioprinting Tumor Models: Recent Advances in Their Applications

Study on Development of Composite Hydrogels With Tunable Structures and Properties for Tumor-on-a-Chip Research